Answers are grounded in this paper and cite their sources.
Cancer continues to be the leading cause of death globally, with mounting evidence associating cellular stress with tumor initiation, progression, and therapeutic resistance. DNA damage-inducible transcript 3 (DDIT3), a key stress-responsive transcription factor, plays a central role in cellular stress responses by regulating apoptosis, cell survival, and the tumor microenvironment. Although DDIT3 has been extensively studied in neurodegenerative and metabolic diseases, its dual role in cancer has only recently begun to emerge. This review systematically explores the intricate functions of DDIT3 in cancer biology, emphasizing its involvement in endoplasmic reticulum (ER) stress, apoptosis regulation, and modulation of the tumor microenvironment. We investigate how DDIT3 interacts with key signaling pathways and its impact on cellular stress responses, such as autophagy and macrophage recruitment within the tumor microenvironment. Furthermore, we evaluate the therapeutic potential of targeting DDIT3 through clinical and preclinical drug studies, concentrating on compounds that enhance its pro-apoptotic functions or inhibit its cancer-promoting activities. This review seeks to provide a comprehensive understanding of DDIT3′s role in tumors, offering insights into future therapeutic strategies targeting this stress-related protein in oncology.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: